273 related articles for article (PubMed ID: 23529876)
1. Improvement of CNS defects via continuous intrathecal enzyme replacement by osmotic pump in mucopolysaccharidosis type II mice.
Sohn YB; Lee J; Cho SY; Kim SJ; Ko AR; Nam MH; Jin DK
Am J Med Genet A; 2013 May; 161A(5):1036-43. PubMed ID: 23529876
[TBL] [Abstract][Full Text] [Related]
2. Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II.
Cho SY; Lee J; Ko AR; Kwak MJ; Kim S; Sohn YB; Park SW; Jin DK
Orphanet J Rare Dis; 2015 Oct; 10():141. PubMed ID: 26520066
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
[TBL] [Abstract][Full Text] [Related]
4. Changes in glycogen and glycosaminoglycan levels in hepatocytes of iduronate-2-sulfatase knockout mice before and after recombinant iduronate-2-sulfatase supplementation.
Lee JH; Choe YH; Kim SJ; Paik KH; Jin DK
Yonsei Med J; 2011 Mar; 52(2):263-7. PubMed ID: 21319344
[TBL] [Abstract][Full Text] [Related]
5. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome.
Arguello A; Meisner R; Thomsen ER; Nguyen HN; Ravi R; Simms J; Lo I; Speckart J; Holtzman J; Gill TM; Chan D; Cheng Y; Chiu CL; Dugas JC; Fang M; Lopez IA; Solanoy H; Tsogtbaatar B; Zhu Y; Bhalla A; Henne KR; Henry AG; Delucchi A; Costanzo S; Harris JM; Diaz D; Scearce-Levie K; Sanchez PE
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622797
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
[TBL] [Abstract][Full Text] [Related]
7. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
[TBL] [Abstract][Full Text] [Related]
8. Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy.
Miwa S; Watabe AM; Shimada Y; Higuchi T; Kobayashi H; Fukuda T; Kato F; Ida H; Ohashi T
Mol Genet Metab; 2020 Aug; 130(4):262-273. PubMed ID: 32631737
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology.
Sohn YB; Ko AR; Seong MR; Lee S; Kim MR; Cho SY; Kim JS; Sakaguchi M; Nakazawa T; Kosuga M; Seo JH; Okuyama T; Jin DK
J Inherit Metab Dis; 2018 Nov; 41(6):1235-1246. PubMed ID: 29978271
[TBL] [Abstract][Full Text] [Related]
10. Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles.
Rigon L; Salvalaio M; Pederzoli F; Legnini E; Duskey JT; D'Avanzo F; De Filippis C; Ruozi B; Marin O; Vandelli MA; Ottonelli I; Scarpa M; Tosi G; Tomanin R
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31022913
[TBL] [Abstract][Full Text] [Related]
11. Auditory characteristics and therapeutic effects of enzyme replacement in mouse model of the mucopolysaccharidosis (MPS) II.
Hong SH; Chu H; Kim KR; Ko MH; Kwon SY; Moon IJ; Chung WH; Cho YS; Kim CH; Suh MW; Choi EW; Sohn YB; Park SW; Kim SH; Cho SY; Ko AR; Jin DK
Am J Med Genet A; 2012 Sep; 158A(9):2131-8. PubMed ID: 22847837
[TBL] [Abstract][Full Text] [Related]
12. Enzyme augmentation therapy enhances the therapeutic efficacy of bone marrow transplantation in mucopolysaccharidosis type II mice.
Akiyama K; Shimada Y; Higuchi T; Ohtsu M; Nakauchi H; Kobayashi H; Fukuda T; Ida H; Eto Y; Crawford BE; Brown JR; Ohashi T
Mol Genet Metab; 2014 Feb; 111(2):139-46. PubMed ID: 24100247
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic Correction of Murine Mucopolysaccharidosis Type II by Engraftment of
Smith MC; Belur LR; Karlen AD; Erlanson O; Podetz-Pedersen KM; McKenzie J; Detellis J; Gagnidze K; Parsons G; Robinson N; Labarre S; Shah S; Furcich J; Lund TC; Tsai HC; McIvor RS; Bonner M
Hum Gene Ther; 2022 Dec; 33(23-24):1279-1292. PubMed ID: 36226412
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome).
Gusarova VD; Smolov MA; Lyagoskin IV; Degterev MB; Rechetnik EV; Rodionov AV; Pantyushenko MS; Shukurov RR
BioDrugs; 2023 May; 37(3):375-395. PubMed ID: 37014547
[TBL] [Abstract][Full Text] [Related]
16. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil.
Giugliani R; Martins AM; So S; Yamamoto T; Yamaoka M; Ikeda T; Tanizawa K; Sonoda H; Schmidt M; Sato Y
Mol Ther; 2021 Jul; 29(7):2378-2386. PubMed ID: 33781915
[TBL] [Abstract][Full Text] [Related]
17. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
[TBL] [Abstract][Full Text] [Related]
18. Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy.
Maccari F; Rigon L; Mantovani V; Galeotti F; Salvalaio M; D'Avanzo F; Zanetti A; Capitani F; Gabrielli O; Tomanin R; Volpi N
J Mol Med (Berl); 2022 Aug; 100(8):1169-1179. PubMed ID: 35816218
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy.
Jung SC; Park ES; Choi EN; Kim CH; Kim SJ; Jin DK
Mol Cells; 2010 Jul; 30(1):13-8. PubMed ID: 20652491
[TBL] [Abstract][Full Text] [Related]
20. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder.
Calias P; Papisov M; Pan J; Savioli N; Belov V; Huang Y; Lotterhand J; Alessandrini M; Liu N; Fischman AJ; Powell JL; Heartlein MW
PLoS One; 2012; 7(1):e30341. PubMed ID: 22279584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]